Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus
Bansal, Ajay , Gupta, Vijayalaxmi , Wang, Kenneth T.

Mayo Clinic

Journal of Cellular Biochemistry | January 25, 2016 | Volume: 117 | Issue: 6 | Pages: 1288-1295

10.1002/jcb.25497 | PMID 26808728 Get It

ABSTRACTThe rapid increase and poor survival of esophageal adenocarcinoma (EAC) have led to significant efforts to promote early detection. Given that the premalignant lesion of Barrett's esophagus (BE) is the major known risk factor for EAC, multiple investigators have studied biomarker signatures that can predict malignant progression of BE to EAC. MicroRNAs, a novel class of gene regulators, are small non‐coding RNAs and have been associated with carcinogenesis. MicroRNAs are ideal biomarkers because of their remarkable stability in fixed tissues, a common method for collection of clinical specimens, and in blood either within exosomes or as microRNA‐protein complexes. Multiple studies show potential of microRNAs as tissue and blood biomarkers for diagnosis and prognosis of EAC but the results need confirmation in prospective studies. Although head‐to‐head comparisons are lacking, microRNA panels require less genes than messenger RNA panels for diagnosis of EAC in BE. MicroRNA diagnostic panels will need to be compared for accuracy against global measures of genome instability that were recently shown to be good predictors of progression but require sophisticated analytic techniques. Early studies on blood microRNA panels are promising but have found microRNA markers to be inconsistent among studies. MicroRNA expression in blood is different between various microRNA sub‐compartments such as exosomes and microRNA‐protein complexes and could affect blood microRNA measurements. Further standardization is needed to yield consistent results. We have summarized the current understanding of the tissue and blood microRNA signatures that may predict the development and progression of EAC. J. Cell. Biochem. 117: 1288–1295, 2016. © 2016 Wiley Periodicals, Inc.
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine
Kattan, Michael W. , Hess, Kenneth R. , Amin, Mahul B. , Lü, Ying , Moons, Karl G.M., Gershenwald, Jeffrey E. , Gimotty, Phyllis A. , Guinney, Justin , Halabi, Susan , Lazar, Alexander J. , Mahar, Alyson , Weiser, Martin R. , Compton, Carolyn C. , Core, members of the AJCC Precision Medicine, Compton, Carolyn, Patel, Tushar P , Sargent, Daniel J. , Core, members of the AJCC Precision Medicine, Mahar, Alyson L , Lazar, Alexander J , Halabi, Susan , Lu, Ying , Kattan, Michael W

Mayo Clinic

CA: A Cancer Journal for Clinicians | January 19, 2016 | Volume: 66 | Issue: 5 | Pages: 370-374

10.3322/caac.21339 | PMID 26784705 Get It

The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2‐day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374. © 2016 American Cancer Society.
New Daily Persistent Headache Is Most Likely to Begin at the Start of School
Grengs, Leah R., Mack, Kenneth J.

Mayo Clinic

Journal of Child Neurology | January 5, 2016 | Volume: 31 | Issue: 7 | Pages: 864-868

10.1177/0883073815624761 | PMID 26733504 Get It

This study was performed to determine if there were a time of year that children were more likely to transition into a chronic daily headache. We retrospectively reviewed records of 103 patients with chronic migraine and 104 patients with new daily persistent headache. Of these, 56 chronic migraine and 92 new daily persistent headache patients were able to identify the specific month in which they began to experience daily headaches. Thirty-nine percent of new daily persistent headache patients had an onset of daily headache in either September or January, months traditionally associated with the start of the school semester in the United States. Only a single patient reported onset in May or June. Data for the transition from episodic to chronic migraine also showed higher rates in September and January, but did not reach statistical significance. These data demonstrate the higher rates of new daily persistent headache onset during school start months and question what factors may be responsible for this association.
Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry
Kim, Sung Hee, Piccini, Jonathan P. , Reiffel, James A. , Thomas, Laine , Chang, Paul, Fonarow, Gregg C. , Go, Alan S. , Mahaffey, Kenneth W. , Kowey, Peter R. , Jackson, Larry R. , Gersh, Bernard J. , Naccarelli, Gerald V. , Freeman, James V. , Peterson, Eric D.

Mayo Clinic

Clinical Cardiology | December 31, 2015 | Volume: 39 | Issue: 2 | Pages: 119-125

10.1002/clc.22504 | PMID 26720750 Get It

ABSTRACTBackgroundPatients with sinus node dysfunction (SND) have increased risk of atrial tachyarrhythmias, including atrial fibrillation (AF). To date, treatment patterns and outcomes of patients with SND and AF have not been well described.HypothesisPatients with SND and AF have higher risk of adverse cardiovascular outcomes.MethodsSinus node dysfunction was defined clinically, based on treating physician. Treatment patterns were described and logistic regression analysis performed to assess outcomes.ResultsOverall, 1710 (17.7%) out of 9631 patients had SND at enrollment. Patients with SND and AF had increased comorbid medical illnesses, more severe symptoms (European Heart Rhythm Association class IV: 17.5% vs 13.9%; P = 0.0007), and poorer quality of life (median 12‐month Atrial Fibrillation Effect on Quality of Life score: 79.6 vs 85.2; P = 0.0008). There were no differences in AF management strategy between patients with SND and those without (rate control, 69.7% vs 67.7%; rhythm control, 30.0% vs 32.0%; P = 0.11). After adjustment, patients with SND were more likely than those without SND to progress from paroxysmal AF at baseline to persistent or permanent AF at any follow‐up, or persistent AF at baseline to permanent AF at any follow‐up (odds ratio: 1.23, 95% confidence interval: 1.01‐1.49, P = 0.035). However, there was no association between SND and major risk‐adjusted outcomes.ConclusionsSinus node dysfunction is present in 1 of 6 patients with AF and is associated with increased comorbidities and higher symptom burden. However, SND is not associated with an increase in major risk‐adjusted outcomes.
SCAI/ACC/HRS institutional and operator requirements for left atrial appendage occlusion
Kavinsky, Clifford J. , Bavry, Anthony A. , Bailey, Steven R. , Ellenbogen, Kenneth A. , Hess, Paul L. , Lustgarten, Daniel L. , Moussa, Issam , Spies, Christian , Spies, Claudia , Kusumoto, Fred M, Kusumoto, Fred , Spies, Claudia D , Ellenbogen, Kenneth A

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 10, 2015 | Volume: 87 | Issue: 3 | Pages: 351-362

10.1002/ccd.26381 | PMID 26663263 Get It

© 2016 Heart Rhythm Society, the American College of Cardiology Foundation, and the Society for Cardiovascular Angiography and Interventions
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer
Roberts, Nicholas J. , Norris, Alexis L. , Petersen, Gloria M. , Bondy, Melissa L. , Gallinger, Steven , Kurtz, Robert C. , Olson, Sara H. , Rustgi, Anil K. , Schwartz, Ann G. , Zogopoulos, George , Ali, Syed Z. , Axilbund, Jennifer E., Chaffee, Kari G. , Childs, Erica J., Herman, Joseph M. , Kramer, Melissa , Makohon-Moore, Alvin P. , McCombie, W. Richard , McMahon, K. Wyatt, Niknafs, Noushin , Parla, Jennifer, Pirooznia, Mehdi , Potash, James B. , Rhim, Andrew D. , Smith, Alyssa , Wolfgang, Christopher L. , Wood, Laura D. , Zandi, Peter P. , Karchin, Rachel , Eshleman, James R. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Hruban, Ralph H. , Rabe, Kari G. , Brand, Randall E. , Stoffel, Elena M. , Syngal, Sapna , Chen, Yunching , Coté, Michele L. , Douville, Christopher , Goes, Fernando , Iacobuzio–Donahue, Christine A. , Wang, Yuxuan , Goggins, Michael , Klein, Alison P. , Pirooznia, Mehdi

Mayo Clinic

Cancer Discovery | December 9, 2015 | Volume: 6 | Issue: 2 | Pages: 166-175

10.1158/2159-8290.cd-15-0402 | PMID 26658419 Get It

Abstract Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. A familial aggregation of pancreatic cancer has been established, but the cause of this aggregation in most families is unknown. To determine the genetic basis of susceptibility in these families, we sequenced the germline genomes of 638 patients with familial pancreatic cancer and the tumor exomes of 39 familial pancreatic adenocarcinomas. Our analyses support the role of previously identified familial pancreatic cancer susceptibility genes such as BRCA2, CDKN2A, and ATM, and identify novel candidate genes harboring rare, deleterious germline variants for further characterization. We also show how somatic point mutations that occur during hematopoiesis can affect the interpretation of genome-wide studies of hereditary traits. Our observations have important implications for the etiology of pancreatic cancer and for the identification of susceptibility genes in other common cancer types. Significance: The genetic basis of disease susceptibility in the majority of patients with familial pancreatic cancer is unknown. We whole genome sequenced 638 patients with familial pancreatic cancer and demonstrate that the genetic underpinning of inherited pancreatic cancer is highly heterogeneous. This has significant implications for the management of patients with familial pancreatic cancer. Cancer Discov; 6(2); 166–75. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients
Advani, Ranjana H. , Ansell, Stephen M. , Lechowicz, Mary Jo , Beaven, Anne , Loberiza, Fausto R., Carson, Kenneth R. , Evens, Andrew M. , Pro, Barbara, Pinter‐Brown, Lauren , Smith, Sonali M. , Shustov, Andrei R., Foss, Francine M. , Horwitz, Steven M. , Savage, Kerry J. , Vose, Julie M. , Advani, Ranjana H , Evens, Andrew M

Mayo Clinic

British Journal of Haematology | December 2, 2015 | Volume: 172 | Issue: 4 | Pages: 535-544

10.1111/bjh.13855 | PMID 26627450 Get It

Summary Peripheral T‐cell lymphomas ( PTCL ) have suboptimal outcomes using conventional CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti‐folate pralatrexate, the first drug approved for patients with relapsed/refractory PTCL , provided a rationale to incorporate it into the front‐line setting. This phase 2 study evaluated a novel front‐line combination whereby cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) alternated with pralatrexate ( CEOP ‐P) in PTCL . Patients achieving a complete or partial remission ( CR / PR ) were eligible for consolidative stem cell transplantation ( SCT ) after 4 cycles. Thirty‐three stage II ‐ IV PTCL patients were treated: 21 PTCL ‐not otherwise specified (64%), 8 angioimmunoblastic T cell lymphoma (24%) and 4 anaplastic large cell lymphoma (12%). The majority (61%) had stage IV disease and 46% were International Prognostic Index high/intermediate or high risk. Grade 3–4 toxicities included anaemia (27%), thrombocytopenia (12%), febrile neutropenia (18%), mucositis (18%), sepsis (15%), increased creatinine (12%) and liver transaminases (12%). Seventeen patients (52%) achieved a CR . The 2‐year progression‐free survival and overall survial, were 39% (95% confidence interval 21–57) and 60% (95% confidence interval 39–76), respectively. Fifteen patients (45%) (12 CR ) received SCT and all remained in CR at a median follow‐up of 21·5 months. CEOP ‐P did not improve outcomes compared to historical data using CHOP . Defining optimal front line therapy in PTCL continues to be a challenge and an unmet need.
Pulmonary IgG4‐related disease and colon adenocarcinoma: possible paraneoplastic syndrome
Krause, Megan L., Yi, Eunhee S. , Warrington, Kenneth J. , Warrington, Kenneth J

Mayo Clinic

International Journal of Rheumatic Diseases | December 1, 2015 | Volume: 20 | Issue: 5 | Pages: 654-656

10.1111/1756-185x.12806 | PMID 26620534 Get It

AbstractMalignancy has a complicated association with immunoglobulin G4‐related disease (IgG4‐RD) both being an item in the differential diagnosis as well as malignancy occurring in the background of IgG4‐RD in the same organ. However, recently there is evidence of higher rates of distant malignancy in patients with IgG4‐RD. Here we report a case of pulmonary IgG4‐RD potentially consistent with a paraneoplastic phenomenon which improved with treatment of the underlying colon adenocarcinoma.
Co‐registration of angiography and intravascular ultrasound images through image‐based device tracking
Prasad, Megha , Cassar, Andrew, Fetterly, Kenneth A. , Bell, Malcolm R. , Theessen, Heike, Ecabert, Olivier, Bresnahan, John F., Bell, Malcolm, Lerman, Amir

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 28, 2015 | Volume: 88 | Issue: 7 | Pages: 1077-1082

10.1002/ccd.26340 | PMID 26614387 Get It

ObjectivesTo determine the feasibility of automated co‐registration of angiography and intravascular ultrasound (IVUS) to facilitate integration of these two imaging modalities in a synchronous manner.BackgroundIVUS provides cross‐sectional imaging of coronary arteries but lacks overview of the vascular territory provided by angiography. Co‐registration of angiography and IVUS would increase utility of IVUS in the clinical setting.MethodsForty‐nine consecutive patients undergoing surveillance for cardiac allograft vasculopathy with angiography and IVUS of the left anterior descending artery (LAD) were enrolled. A pre‐IVUS angiogram of the LAD was performed followed by an ECG‐triggered fluoroscopy (ECGTF) during IVUS pullback at 0.5 mm/s using an automatic pullback device. ECGTF was used to track the IVUS catheter during pullback and establish a spatial relationship to the pre‐IVUS angiogram. Angio‐IVUS co‐registration was performed with a research prototype (Siemens Healthcare, Germany) and accuracy was evaluated by distance mismatch between angiography and IVUS images at vessel bifurcations.ResultsMedian age was 54 (44.5, 67) years. The population was 82.6% male with minimal risk factors. The median (IQR) co‐registration distance mismatch measured at 108 bifurcations in 42 (85%) patients was 0.35 (0.00–1.16) mm. Seven patients were excluded due to inappropriate data acquisition (n = 3) and failure of tracking (n = 4), e.g., due to overlapping sternal wires. Estimated effective radiation dose for ECGTF was 0.09 mSv.ConclusionThis study demonstrates the feasibility of angio‐IVUS co‐registration which may be used as a clinical tool for localizing IVUS cross‐sections along an angiographic roadmap. © 2015 Wiley Periodicals, Inc.